Reshema Kemps-Polanco, you rejoined Novartis in 2022 to lead the commercial oncology business in the United States. What was the motivation to return to Novartis?
答:
There were two major aspects that attracted me to rejoin Novartis: one deeply personal, the other linked to my ability to restructure businesses to reflect swiftly changing market realities...
English
保存
分享
更多
